Two Types of PRF Membranes in Management of Dehiscence Defect in Posterior Mandible

Alexandria University20 enrolled

Overview

Background: Placement of implants in an atrophic posterior ridge is a challenge for so many clinicians. The success of dental implants depends on the volume of alveolar bone available to provide stability. Bone grafting using xenograft with PRF and e-PRF as a membrane has shown promising results in both bone healing and defect reconstruction. Aim of the study: to evaluate the effect of Platelet-rich fibrin (PRF) and Extended Platelet-rich fibrin (e-PRF) as a membrane with xenograft to increase the width of ridge in posterior mandible with simultaneous implant placement.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Atrophic Mandible

Interventions

e-PRF membrane will be used with xenograft simultaneously with implant placement.OTHER

Peripheral blood is collected in plain tubes and centrifuged (700-2000 g, 8 min) to separate plasma from red cells. The first 2-4 mL of platelet-poor plasma (PPP) is withdrawn and heated at 75 °C for 10 minutes to form albumin gel, then cooled for 1-2 minutes. Meanwhile, the remaining blood fractions (buffy coat, liquid PRF, red cells) are kept cooled to prevent premature clotting.

PRF membrane will be used with xenograft simultaneously with implant placementOTHER

Peripheral blood is collected in 9-10 mL additive-free tubes and centrifuged horizontally at 700-2000 g for 8 minutes.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with one or more missing posterior mandibular teeth. * Patient with atrophic posterior mandible with residual ridge width in the range of 4 to 6mm. * Patient with good oral hygiene and acceptable inter-arch space less than or equal to the restoration Exclusion Criteria: * The patient underwent alveolar ridge reconstruction in the same area. * Patients with immune diseases, uncontrolled hypertension, and uncontrolled diabetes. * Patient with any pathological condition at the site of surgery. * Heavy smoker, alcohol abuse, parafunctional habits.

Locations (1)

Outpatient Clinic of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Alexandria University, Egypt

Alexandria, Azarita, Egypt

Outcomes

Primary Outcomes

Change in implant stability

Osstell device will be used to measure the implant stability, primary stability Just after implant placement, and secondary stability 6 months from the time of implant placement. The measured values will be recorded in ISQ from 1 to 100, Implant stability is directly proportional to ISQ value

Time frame: baseline and 6 months

Secondary Outcomes

change in pain scores

Visual Analogue Scale (VAS) will be used to assess pain for 7 days postoperatively using a 10-point (0-1= None, 2-4= Mild, 5-7= Moderate, 8-10= Severe)

Time frame: uo to 7 days

Change in edema scores

Assessment of edema will be done immediately, post-operative on the 2nd, 3rd, and 7th days as follows: no inflammation= none intraoral swelling confined to the surgical field = mild extraoral swelling in the surgical zone= moderate extraoral swelling spreading beyond the surgical zone= intense

Time frame: up to 7 days

change in bone width gain

CBCT will be used

Time frame: baseline and 6 months

change in bone density

CBCt will be used

Time frame: baseline and 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.